Equipped with what it sees as a strong R&D workforce and sufficient capital, D&D Pharmatech is set to begin a new chapter after growing rapidly since its establishment in 2014.
The South Korea-headquartered biotech, which focuses on innovative first-in-class therapeutics for neurodegenerative and fibrotic diseases, has so far raised $150m in series A and B financings, marking the biggest fundraising by a private Korean biotech last